In the Making a Difference series, KCCure’s Director of Patient Engagement, Laura Loughlin will be highlighting organizations making a difference in Kidney Cancer research. In this first article, we’re profiling work being done at the Broad Institute researching rare kidney cancer. The Broad Institute of Cambridge and Harvard Located in Cambridge, MA the Broad is a non-profit research organization partnered with MIT, Harvard and the five Harvard teaching hospitals. On October 18th I had the opportunity to visit the Broad. I attended a Pre-Launch Workshop for the Rare Cancer Dependency Map Initiative. This initiative provides a patient driven research platform seeking treatments for rare kidney cancers. The research starts with patients’ authorizing donation of fresh tissue...
For the second year in a row, KCCure represented kidney cancer patients at the annual meeting for the American Urological Association. This year, KCCure was instrumental in planning for the meeting by serving on the AUA Steering Committee for Patient Advocacy Efforts.
“Today’s decision by the FDA is a game-changer for patients and physicians managing advanced kidney cancer,” said Hans Hammers M.D., Ph.D., KCCure co-founder and senior co-author of the clinical study for the combination.
KCCure joined with twelve other kidney cancer advocacy organizations urging Congress to double kidney cancer research funding for the Kidney Cancer Research Program (KCRP) administered by the Congressionally Directed Medical Research Program (CDMRP).
Today's Voice of Kidney Cancer is Dr. Elizabeth (Lisa) Henske, who runs the Henske Lab at Brigham and Women's Hospital and Harvard Medical School in Boston. One of her principal areas of research is chromophobe renal cell carcinoma (chRCC). She's also one of the newest members of the KCCure scientific advisory board. We're grateful to Dr. Henske for donating her time to answer a few questions about her work in chRCC.
The 2018 Genitourinary (GU) Cancers Symposium is a three-day scientific and educational meeting focusing on research and clinical applications in GU cancers (which includes kidney, prostate and bladder). For the second year in a row, KCCure participated in this important kidney cancer conference.
Register today to learn more about how to apply for new kidney cancer funding! Kidney cancer research funding will be provided for the fiscal year 2017 (FY17) through a new, $10 million, stand-alone program in the Department of Defense Congressionally Directed Medical Research Programs.
KCCure's Kidney Cancer Research Priorities were developed in response to a survey conducted for the newly formed Kidney Cancer Research Program (KCRP). Advice and suggestions were gathered from our National Patient Advisory Board and our Scientific Advisory Board.
The Kidney Cancer Research Alliance (KCCure) announced today that their first research grant of $100,000 has been awarded to Dr. Wayne Marasco, at Dana Farber Cancer Center for his proposal: CAR T-Cell Factories that change the Tumor Microenvironment to Achieve RCC Cures.